Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee
Restricted accessResearch articleFirst published online October, 2025
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee
Digital ulcers are an important disease manifestation of systemic sclerosis and are associated with significant morbidity. As such, there is an urgent need for the development of evidence-based recommendations to guide clinicians in the treatment of digital ulcers.
Methods:
A steering committee of international experts was established. A systematic review of the literature pertaining to the use of pharmacologic treatments in the management of digital ulcers was performed to inform the development of treatment recommendations for systemic sclerosis digital ulcers. Consensus methodology was used to develop the final treatment recommendations.
Results:
The World Scleroderma Foundation committee agreed on 8 overarching treatment principles and 10 pharmacologic treatment recommendations for the management of systemic sclerosis digital ulcers. Phosphodiesterase 5 inhibitors and intravenous iloprost were recommended for the management of acute digital ulcers. Bosentan was recommended for prevention of digital ulcers.
Conclusion:
This study has yielded pragmatic treatment recommendations to direct treatment decisions for the management of systemic sclerosis digital ulcers. In addition, results have highlighted areas in need of future research in order to improve patient outcomes.
Matucci-CerinicMKriegTGuillevinL, et al. Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. Ann Rheum Dis2016; 75(10): 1770–1776.
3.
HughesMAllanoreYChungL, et al. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol2020; 16(4): 208–221.
4.
MihaiCLandewéRvan der HeijdeD, et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis. Ann Rheum Dis2016; 75(4): 681–686.
5.
MorrisroeKStevensWSahharJ, et al. Digital ulcers in systemic sclerosis: their epidemiology, clinical characteristics, and associated clinical and economic burden. Arthritis Res Ther2019; 21(1): 299.
6.
CampochiaroCSulimanYAHughesM, et al. Non-surgical local treatments of digital ulcers in systemic sclerosis: a systematic literature review. Semin Arthritis Rheum2023; 63: 152267.
7.
SulimanYACampochiaroCHughesM, et al. Surgical management of digital ulcers in systemic sclerosis: a systematic literature review. Semin Arthritis Rheum2023; 63: 152266.
8.
HughesMAlcacer-PitarchBGheorghiuAM, et al. Digital ulcer debridement in systemic sclerosis: a systematic literature review. Clin Rheumatol2020; 39(3): 805–811.
9.
LebedoffNFrechTMShanmugamVK, et al. Review of local wound management for scleroderma-associated digital ulcers. J Scleroderma Relat Disord2018; 3(1): 66–70.
10.
RossLMaltezNHughesM, et al. Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review. Rheumatology2023; 62: 3785–3800.
11.
BurnsPBRohrichRJChungKC.The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg2011; 128(1): 305–310.
12.
AndriguetiFVEbbingPCCArismendiMI, et al. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clin Exp Rheumatol2017; 35 (suppl106)(4): 151–158.
13.
HachullaEHatronPYCarpentierP, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis2016; 75(6): 1009–1015.
14.
ShenoyPDKumarSJhaLK, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology2010; 49(12): 2420–2428.
15.
BruecknerCSBeckerMOKroenckeT, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis2010; 69(8): 1475–1478.
16.
KumarUSankalpGSreenivasV, et al. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications. Rheumatol Int2013; 33(4): 1047–1052.
17.
Della RossaADoveriMD’AscanioA, et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol2011; 40(4): 323–325.
18.
WigleyFMSeiboldJRWiseRA, et al. Intravenous iloprost treatment of Raynaud’s phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol1992; 19(9): 1407–1414.
19.
WigleyFMWiseRASeiboldJR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med1994; 120(3): 199–206.
20.
Abou-RayaAAbou-RayaSHelmiiM.Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol2008; 35(9): 1801–1808.
21.
KhannaDDentonCPMerkelPA, et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA2016; 315(18): 1975–1988.
22.
KornJHMayesMMatucci CerinicM, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum2004; 50(12): 3985–3993.
23.
Matucci-CerinicMDentonCPFurstDE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis2011; 70(1): 32–38.
24.
Meyrick ThomasRHRademakerMGrimesSM, et al. Nifedipine in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis. Br J Dermatol1987; 117(2): 237–241.
25.
Kahan AAmorBMenkesCJ, et al. Nifedipine in digital ulceration in scleroderma. Arthritis Rheum1983; 26(6): 809.
26.
DentonCPHachullaÉRiemekastenG, et al. Efficacy and safety of selexipag in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase ii study. Arthritis Rheumatol2017; 69(12): 2370–2379.
27.
SeiboldJWigleyFSchiopuE, et al. Digital ulcers in SSC treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up. J Scleroderma Relat Disord2017; 2: 42–49.
28.
VayssairatM.Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French microcirculation society multicenter group for the study of vascular acrosyndromes. J Rheumatol1999; 26(10): 2173–2178.
29.
KhorCGChenXLLinTS, et al. Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Clin Rheumatol2014; 33(7): 1019–1020.
30.
ZachariaeHHalkier -SorensenLHeicken dorffL, et al. Cyclosporin a treatment of systemic sclerosis. Br J Dermatol1990; 122(5): 677–681.
31.
DauPCKahalehMBSagebielRW.Plasmapheresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum1981; 24(9): 1128–1136.
32.
KaralilovaRVBatalovZASapundzhievaTL, et al. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int2021; 41(10): 1743–1753.
33.
NagarajaVSpinoCBushE, et al. A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. Arthritis Res Ther2019; 21(1): 202.
34.
KlimiukPSKayEAMitchellWS, et al. Ketanserin: an effective treatment regimen for digital ischaemia in systemic sclerosis. Scand J Rheumatol1989; 18(2): 107–111.
35.
BeckettVLConnDLFusterV, et al. Trial of platelet-inhibiting drug in scleroderma. Double-blind study with dipyridamole and aspirin. Arthritis Rheum1984; 27(10): 1137–1143.
36.
NtelisKGkizasVFilippopoulouA, et al. Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study. BMC Musculoskelet Disord2016; 17: 213.
37.
HughesMAllanoreYEl AoufyK, et al. A practical approach to the management of digital ulcers in patients with systemic sclerosis: a narrative review. JAMA Dermatol2021; 157(7): 851–858.
38.
GiuggioliDManfrediAColaciM, et al. Osteomyelitis complicating scleroderma digital ulcers. Clin Rheumatol2013; 32(5): 623–627.
39.
GiuggioliDManfrediAColaciM, et al. Scleroderma digital ulcers complicated by infection with fecal pathogens. Arthritis Care Res2012; 64(2): 295–297.
40.
AuKMayesMDMaranianP, et al. Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. Arthritis Care Res2010; 62(12): 1772–1778.
41.
GaraimanASteigmillerKGebhardC, et al. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology2023; 62(Si): Si91–si100.
42.
RossLHansenDMaltezN, et al. The effect of calcium channel blockers on digital ulcers in systemic sclerosis: data from a prospective cohort study. Clin Rheumatol2024; 43(1): 269–276.
43.
GaldoFDLescoatAConaghanPG, et al. OP0234 2023 update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases2023; 82(suppl 1): 154.
44.
HughesMPaulingJDJonesJ, et al. Multicenter qualitative study exploring the patient experience of digital ulcers in systemic sclerosis. Arthritis Care Res2020; 72(5): 723–733.
